Avid Bioservices Inc (CDMO)

[EYEBUYSTOX]

This is a great read about HCC trials:

http://www.nature.com/nature/journal/v516/n7529_supp/full/516S4a.html

Of course, bavituximab isn't mentioned. But it really underscores how hard HCC is to treat. It also reiterates how important a partner can be in advancing a drug in this indication.

There are lots of others out there with more money and equally impressive results. From the article:

In a randomized phase II trial of 30 patients with advanced liver cancer, high doses of Pexa-Vec resulted in a median survival time of more than 14 months: twice the survival time for patients on placebo3. A phase III trial is slated to begin next year in partnership with the biotech company Transgene (based in Strasbourg, France) and Lee's Pharmaceutical (based in Hong Kong).